Login to Your Account



Clinic Roundup


Thursday, January 3, 2013
• Astex Pharmaceuticals Inc., of Dublin, Calif., said it started a Phase II study testing SGI-110 in advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription